An immune-active tumor microenvironment favors clinical response to ipilimumab
By Rui-Ru Ji, S. Chasalow, Lisu Wang, O. Hamid, H. Schmidt, J. Cogswell, S. Alaparthy, D. Berman, M. Jure-Kunkel, N. Siemers and 2 more. Cancer Immunology and Immunotherapy, 2012
722 citations recorded by the source corpus.
Subfields: Genetics, Immunology, Oncology
View Paper: https://www.semanticscholar.org/paper/98b76a17ce5f1cb8ab356a8bb2a6f4e865f0f00d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Immunology
In Oncology
Citations in the corpus
- Profiling tumor infiltrating immune cells with CIBERSORT (2018, background): “Recent studies have found that T lymphocyte subsets (e.g., CD8+) may predict response to existing and emerging immunotherapies, highlighting the importance of investigating tumor associated immune cells as potential predictive biomarkers [3–5].”
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells (2013, background): “Indeed, response to ipilimumab has been associated with the presence of tumor-infiltrating lymphocytes (43, 44).”
- Molecular and genetic properties of tumors associated with local immune cytolytic activity (2015, positive): “…of outcome have been identified in the context of spontaneous tumor immunity (Bindea et al., 2013) and immunotherapy (Herbst et al., 2014; Tumeh et al., 2014; Ji et al., 2012; Snyder et al., 2014), but there remains a need for more extensive mechanistic analyses of human tumor-immune interactions.”
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features (2017, neutral): “5 g/L 26 (12) 13 (11) 42 (31) Platelet count, 41 (18) 17 (13) N/A AFP, >100 mg/dL (%) 51 (23) 38 (31) 43 (33) Events (%) Recurrence 150 (67) 78 (60) 88 (59) Death 133 (59) 46 (35) 84 (44) Median follow-up, months 49 51 N/A”
- Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy (2018, neutral): “Recent studies suggest that the degree of T cell infiltration— which might be regulated by tumor cell-intrinsic signaling pathways and gene regulatory networks—is a critical factor (Chen et al., 2016; Ji et al., 2012; Kortlever et al., 2017; Peng et al., 2015; Spranger et al., 2015;Wang et al., 2016”
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy (2014, background): “Recent studies associate an inflammatory tumor microenvironmentwith responsiveness to certain formsof immunotherapy such as cancer vaccines and ipilimumab (25, 26),”
- New insights into cancer immunoediting and its three component phases — elimination, equilibrium and escape (2014, positive): “Other signatures have emerged from patients receiving IL-2 [57], MAGE-A3 vaccination [58], and Ipilimumab [59], and many targeted and conventional therapies also display similar lymphocyte signatures [60–62].”
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors (2014, background): “Preliminary data exploring clinical responses to anticytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or antiprogrammed cell death protein 1 (PD-1) mAbs also have suggested that patients with clinical benefit have a preexisting CD8 T cell infiltrate and associated gene signature (Ji et al., 2012”
- Immune Checkpoint Blockade in Cancer Therapy. (2015, background): “Intratumorally, a high number of T regulatory cells, the presence of the immunosuppressive enzyme indoleamine 2,3-dioxygenase, and immune-active genetic profile have been associated with benefit from ipilimumab.(82,83) More recently, whole-exome sequencing of tumors from patients treated with CTLA-4”
- Immunity, inflammation, and cancer: an eternal fight between good and evil. (2015, positive): “However, tumors lacking T cell– based inflammation may require innate immune cells to promote T cell recruitment and activation (50, 71, 72).”
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4 (2013, background): “…blockade to treat melanoma show a positive correlation between IDO expression in pretreatment biopsies and clinical efficacy (Hamid et al., 2011; Ji et al., 2012), and demonstrate no decrease in IDO expression after treatment (Ribas et al., 2009), suggesting that IDO expression may be dependent…”